Lixumistat
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 9, 2017 (NCT03272256)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine/threonine-protein kinase mTORINHIBITOR
MTOR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N=C(NC(=N)N1CCCC1)Nc1ccc(OC(F)(F)F)cc1- Mol. weight
- 315.3 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650733 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05497778 | Phase 1 | Oct 21, 2022 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT03272256 | Phase 1 | Oct 9, 2017 | ImmunoMet Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmunoMet Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1